This unmet clinical need has provided a motivation to systematically investigate tumor response characteristics of advanced NSCLC patients treated with commercially prescribed PD-1 inhibitor therapy, as an initial step to further address this emerging challenge in lung cancer treatment. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.